The Prevalence and Geographic Distribution of Crohn’s Disease and Ulcerative Colitis in the United States

Kappelman, Michael D.; Rifas‐Shiman, Sheryl L.; Kleinman, Ken; Ollendorf, Dan; Bousvaros, Athos; Grand, Richard J.; Finkelstein, Jonathan A.

doi:10.1016/j.cgh.2007.07.012

Cited by 848 publications

(577 citation statements)

References 17 publications

Supporting

Mentioning

529

Contrasting

Unclassified

Order By: Relevance

“…According to United States estimates for CD, incidence varies between 6 and 8 per 100,000 inhabitants, with a prevalence of 100 to 200 per 100,000 inhabitants. In the case of UC, the incidence in that country ranges between 9 and 12, with a prevalence of 205 to 240 per 100,000 inhabitants (15,17,22) . Studies have shown higher rates of incidence of IBD in developing countries, including Brazil (8,34,38) .…”

Section: Introductionmentioning

confidence: 99%

Body Composition in Patients With Crohn’s Disease and Ulcerative Colitis

Back

Marcon

Gaino

et al. 2017

Arq. Gastroenterol.

View full text Add to dashboard Cite

-Background -The nutritional status of individuals with inflammatory bowel diseases is directly related to the severity of the disease and is associated with poor prognosis and the deterioration of immune competence. Objective -To assess the nutritional status and the body composition of outpatients with inflammatory bowel diseases. Methods -A cross-sectional study was conducted with clinical and nutritional assessment of patients with Crohn's disease and ulcerative colitis. Patients were classified according to the clinical activity through Crohn's Disease Activity Index and Mayo Score. Nutritional assessment consisted of anthropometric measurements of current weight, height, mid-arm circumference, triceps skinfold thickness and thickness of adductor policis muscle, with subsequent calculation of BMI, arm muscle circumference and the mid-arm muscle area (MAMA

show abstract

Section: Introductionmentioning

confidence: 99%

Body Composition in Patients With Crohn’s Disease and Ulcerative Colitis

Back

Marcon

Gaino

et al. 2017

Arq. Gastroenterol.

View full text Add to dashboard Cite

show abstract

“…1 In contrast, irritable bowel syndrome (IBS) is a functional GI disorder, affecting 10-20% of individuals worldwide. 2 The etiology of these conditions is uncertain, although some of the proposed pathophysiological mechanisms, including dysregulation of the mucosal immune system and intestinal barrier dysfunction, may be shared.…”

mentioning

confidence: 99%

Negative Effects on Psychological Health and Quality of Life of Genuine Irritable Bowel Syndrome–type Symptoms in Patients With Inflammatory Bowel Disease

Gracie

Williams

Sood

et al. 2017

Clinical Gastroenterology and Hepatology

105

View full text Add to dashboard Cite

“…4,29 Our treated prevalence values, despite missing IBD patients without medical events due to the nature of MEPS data collection, still approximate disease prevalences in literature. 5,30,31 This study's averaging of data over the years from 1996 to 2011 also affects the prevalence values, since prevalence rates have been on a steady rise. 30,31 The strengths of the MEPS database lies in its in-depth, in-person survey design combined with insurer/employer and medical provider components allowing for an unusually comprehensive single source of nationally representative information covering a broad range of clinical care with high granularity, prescription medicines, other medical conditions, socio-demographic information, and detailed insurer and OOP expenditure data.…”

Section: Discussionmentioning

confidence: 99%

“…[1][2][3] IBD is a major chronic disease with per-patient yearly expenditures estimated around $8,265-$11,129 for CD, more costly than diabetes, stroke, coronary artery disease, chronic obstructive pulmonary disease, or multiple sclerosis. 4,5 IBD care spans a particularly wide range of services from inpatient, outpatient, emergency, and office-based settings, and unequal utilization of necessary services by different patient populations carries the potential to create economic waste, avoidable morbidity, and health disparities. 6 In addition, increasing use of medical therapeutics for IBD, in particular biologic agents, create new opportunities for costs to rapidly incur.…”

mentioning

confidence: 99%

Differences in healthcare expenditures for inflammatory bowel disease by insurance status, income, and clinical care setting

Park

Bhattacharya

Park

2014

Preprint

View full text Add to dashboard Cite

View the peer-reviewed version (peerj.com/articles/587), which is the preferred citable publication unless you specifically need to cite this preprint. expenditures for CD, UC, and all IBD were $10,364 (N=238), $7,827 (N=95), and $9,528, respectively, significantly higher than non-IBD ($4,314, N=276,372, p<0.05). Publicly insured patients incurred the highest costs ($18,067), over privately insured ($8,014, p<0.05) or uninsured patients ($5,129, p<0.05). Among all IBD patients, inpatient care composed the highest proportion of costs ($3,392, p<0.05). Inpatient costs were disproportionately higher for publicly insured patients. Public insurance had higher odds of total costs than private (OR 2.13, CI 1.08-4.19) or no insurance (OR 4.94,, with increased odds for inpatient and emergency care. Private insurance had higher costs associated with outpatient care, office-based care, and prescribed medicines. Low-income patients had lower costs associated with outpatient (OR 0.38, CI 0.15-0.95) and office-based care (OR 0.21, CI 0.07-0.62). Conclusions: In the US, high inpatient utilization among publicly insured patients is a previously unrecognized driver of high IBD costs. Bridging this health services gap between SES strata for acute care services may curtail direct IBD-related costs. Disclosures: Authors report no conflicts of interest as described by PeerJAuthor Contributions: Michelle D Park, BA -obtaining funding source, planning and conducting the study, collecting and interpreting data, and drafting/editing the manuscript. Jay Bhattacharya, MD, PhD -planning the study, interpreting data, and editing the manuscript. KT Park, MD, MS -obtaining funding source, planning and conducting the study, collecting and interpreting data, and drafting/editing the manuscript. Aim: To describe IBD-related expenditures based on insurance and household income with the use of inpatient, outpatient, emergency, and office-based services, and prescribed medications in the United States (US). Methods:We evaluated the Medical Expenditure Panel Survey from 1996 to 2011 of individuals with Crohn's disease (CD) or ulcerative colitis (UC). Nationally weighted means, proportions, and multivariate regression models examined the relationships between income and insurance status with expenditures.Results: Annual per capita mean expenditures for CD, UC, and all IBD were $10,364 (N=238), $7,827 (N=95), and $9,528, respectively, significantly higher than non-IBD ($4,314, N=276,372, p<0.05). Publicly insured patients incurred the highest costs ($18,067), over privately insured ($8,014, p<0.05) or uninsured patients ($5,129, p<0.05). Among all IBD patients, inpatient care composed the highest proportion of costs ($3,392, p<0.05). Inpatient costs were disproportionately higher for publicly insured patients. Public insurance had higher odds of total costs than private (OR 2.13, CI 1.08-4.19) or no insurance (OR 4.94,, with increased odds for inpatient and emergency care. Private insurance had higher costs associated with outpatient care, office-b...

show abstract

The Prevalence and Geographic Distribution of Crohn’s Disease and Ulcerative Colitis in the United States

Cited by 848 publications

References 17 publications

Body Composition in Patients With Crohn’s Disease and Ulcerative Colitis

Body Composition in Patients With Crohn’s Disease and Ulcerative Colitis

Negative Effects on Psychological Health and Quality of Life of Genuine Irritable Bowel Syndrome–type Symptoms in Patients With Inflammatory Bowel Disease

Differences in healthcare expenditures for inflammatory bowel disease by insurance status, income, and clinical care setting

Contact Info

Product

Resources

About